ARC 031

Drug Profile

ARC 031

Alternative Names: ARC 031SR; ARC031

Latest Information Update: 21 Mar 2016

Price : $50

At a glance

  • Originator Archer Pharmaceuticals
  • Class Antidementias
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 21 Mar 2016 No recent reports on development identified - Phase-I for Alzheimer's disease in USA (PO, controlled-release)
  • 21 Mar 2016 No recent reports on development identified - Phase-I for Alzheimer's disease in USA (PO, immediate-release)
  • 02 Mar 2010 Phase-I clinical trials in Alzheimer's disease in USA (PO, controlled-release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top